Grey Fox Wealth Advisors’s Moderna MRNA Stock Holding History

Grey Fox Wealth Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-201	Closed	-$5.19K	–	433
2025 Q3	$5.19K	Buy	+201	New	+$5.61K	﹤0.01%	475

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Grey Fox Wealth Advisors's MRNA Position: Q4 2025 in Review

Grey Fox Wealth Advisors sold out of Moderna (MRNA) in Q4 2025, closing a stake of 201 shares — an estimated $5.19K sold.

Grey Fox Wealth Advisors first reported a position in MRNA in Q3 2025 and held it in 1 quarter. The position peaked at $5.19K in Q3 2025. 672 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

Grey Fox Wealth Advisors reported no remaining Moderna position as of Q4 2025 after selling out during the quarter.
Grey Fox Wealth Advisors sold 201 Moderna shares in Q4 2025, an estimated $5.19K.
Grey Fox Wealth Advisors first reported a position in Moderna in Q3 2025 and held it in 1 quarter.
Grey Fox Wealth Advisors's Moderna position peaked at $5.19K in Q3 2025.
672 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on Grey Fox Wealth Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.